BRPI0715712A2 - Composição farmacêutica - Google Patents
Composição farmacêuticaInfo
- Publication number
- BRPI0715712A2 BRPI0715712A2 BRPI0715712-6A2A BRPI0715712A BRPI0715712A2 BR PI0715712 A2 BRPI0715712 A2 BR PI0715712A2 BR PI0715712 A BRPI0715712 A BR PI0715712A BR PI0715712 A2 BRPI0715712 A2 BR PI0715712A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82308306P | 2006-08-21 | 2006-08-21 | |
US60/823083 | 2006-08-21 | ||
PCT/SE2007/000736 WO2008024045A1 (en) | 2006-08-21 | 2007-08-20 | Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0715712A2 true BRPI0715712A2 (pt) | 2014-06-24 |
BRPI0715712B1 BRPI0715712B1 (pt) | 2021-03-23 |
BRPI0715712B8 BRPI0715712B8 (pt) | 2021-05-25 |
Family
ID=39107049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0715712A BRPI0715712B8 (pt) | 2006-08-21 | 2007-08-20 | composição farmacêutica adequada para a administração oral compreendendo um derivado de triazol[4,5d]pirimidina |
Country Status (35)
Country | Link |
---|---|
US (2) | US8425934B2 (pt) |
EP (1) | EP2056832B1 (pt) |
JP (2) | JP5385139B2 (pt) |
KR (1) | KR101539467B1 (pt) |
CN (1) | CN101505754A (pt) |
AR (1) | AR062451A1 (pt) |
AU (2) | AU2007288541B9 (pt) |
BR (1) | BRPI0715712B8 (pt) |
CA (1) | CA2659328C (pt) |
CL (1) | CL2007002421A1 (pt) |
CO (1) | CO6150163A2 (pt) |
CY (1) | CY1119380T1 (pt) |
DK (1) | DK2056832T3 (pt) |
ES (1) | ES2625930T3 (pt) |
HR (1) | HRP20170694T1 (pt) |
HU (1) | HUE031939T2 (pt) |
IL (2) | IL196700A (pt) |
LT (1) | LT2056832T (pt) |
MX (1) | MX340403B (pt) |
MY (2) | MY147966A (pt) |
NO (1) | NO341787B1 (pt) |
NZ (2) | NZ574514A (pt) |
PH (1) | PH12013501627A1 (pt) |
PL (1) | PL2056832T3 (pt) |
PT (1) | PT2056832T (pt) |
RS (1) | RS55884B1 (pt) |
RU (2) | RU2476223C2 (pt) |
SA (1) | SA07280442B1 (pt) |
SG (1) | SG177162A1 (pt) |
SI (1) | SI2056832T1 (pt) |
TW (1) | TWI482772B (pt) |
UA (1) | UA99105C2 (pt) |
UY (1) | UY30551A1 (pt) |
WO (1) | WO2008024045A1 (pt) |
ZA (1) | ZA200900991B (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
CN101208316B (zh) | 2005-08-15 | 2012-05-09 | 贝林格尔·英格海姆国际有限公司 | 制备β-模拟物的方法 |
UY30542A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
EP2515871B1 (en) | 2009-12-23 | 2015-09-23 | ratiopharm GmbH | Solid pharmaceutical dosage form of ticagrelor |
CZ2012705A3 (cs) * | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
EP2813216A1 (en) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Stabilized amorphous ticagrelor |
WO2014170026A1 (en) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
EA201501164A1 (ru) | 2013-05-29 | 2016-08-31 | Рациофарм Гмбх | Твердая фармацевтическая лекарственная форма |
EP2816043A1 (en) | 2013-06-21 | 2014-12-24 | LEK Pharmaceuticals d.d. | Spherical ticagrelor particles |
WO2015001489A1 (en) | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of ticagrelor |
CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
CN104644604A (zh) * | 2013-11-23 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 替格瑞洛倍半水合物胶囊及其制备方法 |
WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
CN104940204A (zh) * | 2014-03-27 | 2015-09-30 | 广东东阳光药业有限公司 | 一种替格瑞洛固体制剂及其制备方法 |
CN104098520B (zh) * | 2014-07-23 | 2016-01-20 | 张远强 | 苯基三唑希夫碱类化合物、其制备方法和用途 |
KR20160012706A (ko) | 2014-07-25 | 2016-02-03 | 동아에스티 주식회사 | 서방성 제제 |
CN105832683A (zh) * | 2015-01-15 | 2016-08-10 | 成都国弘医药有限公司 | 一种含有替格瑞洛的片剂 |
US10300065B2 (en) * | 2015-01-27 | 2019-05-28 | Astrazeneca Ab | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
EP3389634B1 (en) * | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
CN105709230B (zh) * | 2016-03-01 | 2019-05-31 | 北京鑫兰医药科技有限公司 | 一种替格瑞洛药物组合物及其制备方法 |
CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US20170296666A1 (en) | 2016-04-18 | 2017-10-19 | Amneal Pharmaceuticals Company Gmbh | Stable Pharmaceutical Composition Of Amorphous Ticagrelor |
SG10202107682QA (en) | 2016-04-21 | 2021-08-30 | Astrazeneca Ab | Orally disintegrating tablets |
CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
WO2017223229A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
EP3808748A1 (en) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
TR201617983A2 (tr) | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇ |
WO2019170244A1 (en) | 2018-03-08 | 2019-09-12 | Pharmaceutical Oriented Services Ltd. | Ticagrelor—containing tablet formulation |
EA202190328A1 (ru) | 2018-07-27 | 2021-07-01 | КРКА, д.д., НОВО МЕСТО | Фармацевтическая композиция, содержащая тикагрелор |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
AU2020267165B2 (en) | 2020-08-19 | 2024-01-04 | Astrazeneca Ab | Combination treatment |
BR102021011533A2 (pt) * | 2021-06-14 | 2022-12-27 | Libbs Farmacêutica Ltda | Composição farmacêutica e uso da composição farmacêutica |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229674B (en) * | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
SE9904129D0 (sv) | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
IL161996A0 (en) * | 2001-12-21 | 2005-11-20 | Pfizer Prod Inc | Directly compressible formulations of azithromycin |
WO2003068238A1 (en) | 2002-02-15 | 2003-08-21 | Biogal Gyogyszergyar Rt. | Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom |
US20040001885A1 (en) * | 2002-06-27 | 2004-01-01 | Unchalee Kositprapa | Rapidly disintegrating antihistamine formulation |
WO2006085838A1 (en) * | 2005-01-31 | 2006-08-17 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
HN2003000272A (es) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
EP1558218A1 (en) | 2002-10-08 | 2005-08-03 | Ranbaxy Laboratories Limited | Gabapentin tablets and methods for their preparation |
US20060189565A1 (en) * | 2002-10-22 | 2006-08-24 | Mathur Rajeev S | Pharmaceutical compositions of ganciclovir |
SE0203778D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | A new oral immediated release dosage form |
JP2005538038A (ja) * | 2003-02-19 | 2005-12-15 | テバ ジョジセルジャール レースベニュタールシャシャーグ | 規定された粒子サイズの分布を持つザレプロンを含む粉末組成物、及びそれから作られた医薬製品 |
DE10319450A1 (de) | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
JP2005162696A (ja) * | 2003-12-04 | 2005-06-23 | Nichiko Pharmaceutical Co Ltd | 溶出性に優れたセフジトレンピボキシル製剤 |
KR20070026577A (ko) | 2004-05-13 | 2007-03-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 혈소판 억제제 저항성 치료를 위한 디피리다몰의 용도 |
WO2006072878A1 (en) | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
-
2007
- 2007-08-10 TW TW096129721A patent/TWI482772B/zh active
- 2007-08-15 AR ARP070103619A patent/AR062451A1/es not_active Application Discontinuation
- 2007-08-15 SA SA07280442A patent/SA07280442B1/ar unknown
- 2007-08-20 KR KR1020097004259A patent/KR101539467B1/ko active IP Right Review Request
- 2007-08-20 SG SG2011088689A patent/SG177162A1/en unknown
- 2007-08-20 HU HUE07794121A patent/HUE031939T2/en unknown
- 2007-08-20 RU RU2009104330/15A patent/RU2476223C2/ru active
- 2007-08-20 SI SI200731923A patent/SI2056832T1/sl unknown
- 2007-08-20 PL PL07794121T patent/PL2056832T3/pl unknown
- 2007-08-20 US US11/841,030 patent/US8425934B2/en active Active
- 2007-08-20 JP JP2009525520A patent/JP5385139B2/ja active Active
- 2007-08-20 CA CA2659328A patent/CA2659328C/en not_active Expired - Fee Related
- 2007-08-20 MY MYPI20090666A patent/MY147966A/en unknown
- 2007-08-20 CN CNA2007800311371A patent/CN101505754A/zh active Pending
- 2007-08-20 LT LTEP07794121.9T patent/LT2056832T/lt unknown
- 2007-08-20 BR BRPI0715712A patent/BRPI0715712B8/pt active IP Right Grant
- 2007-08-20 ES ES07794121.9T patent/ES2625930T3/es active Active
- 2007-08-20 WO PCT/SE2007/000736 patent/WO2008024045A1/en active Application Filing
- 2007-08-20 MY MYPI2012003213A patent/MY175009A/en unknown
- 2007-08-20 UA UAA200900509A patent/UA99105C2/ru unknown
- 2007-08-20 RS RS20170463A patent/RS55884B1/sr unknown
- 2007-08-20 CL CL200702421A patent/CL2007002421A1/es unknown
- 2007-08-20 MX MX2009001853A patent/MX340403B/es active IP Right Grant
- 2007-08-20 PT PT77941219T patent/PT2056832T/pt unknown
- 2007-08-20 DK DK07794121.9T patent/DK2056832T3/en active
- 2007-08-20 AU AU2007288541A patent/AU2007288541B9/en active Active
- 2007-08-20 UY UY30551A patent/UY30551A1/es not_active Application Discontinuation
- 2007-08-20 EP EP07794121.9A patent/EP2056832B1/en not_active Revoked
- 2007-08-20 NZ NZ574514A patent/NZ574514A/en unknown
- 2007-08-20 NZ NZ596700A patent/NZ596700A/xx unknown
-
2009
- 2009-01-25 IL IL196700A patent/IL196700A/en active IP Right Grant
- 2009-01-28 NO NO20090425A patent/NO341787B1/no unknown
- 2009-02-11 ZA ZA2009/00991A patent/ZA200900991B/en unknown
- 2009-02-20 CO CO09017334A patent/CO6150163A2/es unknown
-
2011
- 2011-08-04 AU AU2011205164A patent/AU2011205164B2/en active Active
-
2012
- 2012-11-28 RU RU2012153069/15A patent/RU2012153069A/ru not_active Application Discontinuation
- 2012-12-21 US US13/724,624 patent/US20130131087A1/en not_active Abandoned
-
2013
- 2013-08-02 PH PH12013501627A patent/PH12013501627A1/en unknown
- 2013-10-02 JP JP2013207138A patent/JP2014040448A/ja active Pending
- 2013-10-29 IL IL229130A patent/IL229130A0/en unknown
-
2017
- 2017-05-10 HR HRP20170694TT patent/HRP20170694T1/hr unknown
- 2017-05-22 CY CY20171100531T patent/CY1119380T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2140867I2 (lt) | Farmacinė kompozicija | |
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
BRPI0715712A2 (pt) | Composição farmacêutica | |
BRPI0719393A2 (pt) | Composição farmacêutica | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
DK2041139T3 (da) | Farmaceutiske forbindelser | |
RU2398586C3 (ru) | Фармацевтическая композиция | |
BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
BRPI0716325A2 (pt) | Composição antimicrobianas | |
BRPI0720234A2 (pt) | Composição farmacêutica | |
RU2493831C3 (ru) | Фармацевтические композиции | |
FR2899479B1 (fr) | Composition cicatrisante | |
DK2073795T3 (da) | Misbrugssikret lægemiddelformulation | |
BRPI0810928A2 (pt) | "composição farmacêutica" | |
DK1940467T3 (da) | Lægemiddelsammensætning med langvarig frigivelse | |
DK1984009T3 (da) | Farmaceutiske sammensætninger med forbedret stabilitet | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
DK1986650T3 (da) | Manipulationssikre doserignsformer | |
BRPI0719398A2 (pt) | Composição farmacêutica. | |
BRPI0719394A2 (pt) | Preparação medicinal sólida | |
BRPI0716458A2 (pt) | Composição de vulcanizado | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
BRPI0817833A2 (pt) | Composição farmacêutica antimalárica | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
BRPI0820198A2 (pt) | composições farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B15V | Prolongation of time limit allowed | ||
B17A | Notification of administrative nullity (patentee has 60 days time to reply to this notification) |
Free format text: REQUERENTE DA NULIDADE: EMS.S.A - 870210086832 - 21/09/2021 |